肠道菌群与儿童非酒精性脂肪性肝病的研究进展

李露; 田云粉

doi:10.12259/j.issn.2095-610X.S20230708

肠道菌群与儿童非酒精性脂肪性肝病的研究进展

doi: 10.12259/j.issn.2095-610X.S20230708

李露,
田云粉^,

昆明理工大学附属医院/云南省第一人民医院儿科，云南昆明　650032

基金项目: 国家自然科学基金资助项目（81760110）；云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目（202201AY070001-253）

详细信息

作者简介:
李露（1995～），女，四川资阳人，在读硕士研究生，主要从事儿科消化临床工作

通讯作者:
田云粉，E-mail：136506595@qq.com

中图分类号: R725.7
计量
- 文章访问数: 2940
- HTML全文浏览量: 2258
- PDF下载量: 29
- 被引次数: 0
出版历程
- 收稿日期: 2022-02-24
- 网络出版日期: 2023-07-18
- 刊出日期: 2023-07-25

Research Progress on Intestinal Microflora and Non-alcoholic Fatty Liver Disease in Children

Lu LI,
Yunfen TIAN^,

Dept. of Pediatrics，The Affiliated Hospital of Kunming University of Science and Technology/ Dept. of Pediatrics，The 1st People’s Hospital of Yunnan Province， Kunming Yunnan 650032，China

摘要

摘要: 儿童非酒精性脂肪性肝病（NAFLD）是全球儿童最常见慢性肝脏疾病，其发病率随着全球肥胖的流行而逐步上升，但缺乏规范、有效的治疗方案。目前其发病机制尚未完全阐明，在众多致病因素中，肠道菌群失调是目前的研究热点，为NAFLD的诊断、预防和治疗开辟了新的方向，但目前对儿童NAFLD的治疗仍在探索中。对近年来肠道菌群及其代谢产物介导儿童NAFLD 的可能机制以及以肠道菌群为干预靶点的诊治方法进行综述，为儿童NAFLD的治疗提供一些新的思路及方法。
- 非酒精性脂肪性肝病 /
- 儿童 /
- 肠道菌群 /
- 肝肠轴 /
- 靶向治疗
Abstract: Pediatric non-alcoholic fatty liver disease （NAFLD） is the most common cause of pediatric chronic liver disease worldwide, and its incidence is gradually increasing with the global epidemic of obesity, but there is no standardized and effective treatment plan. At present, the pathogenesis of NAFLD has not been fully elucidated, Among many pathogenic factors, intestinal microflora disorder is the current research hotspot, which opens up a new direction for the diagnosis, prevention, and treatment of NAFLD. However, the treatment of NAFLD in children is still being explored. In this paper, the possible mechanism of intestinal flora and its metabolites mediating NAFLD in children in recent years was reviewed, as well as the diagnosis and treatment methods using intestinal flora as an intervention target, hoping to provide some new ideas and methods for the treatment of NAFLD in children.
- Non-alcoholic fatty liver disease /
- Children /
- Gut microbiota /
- Gut-liver axis /
- Targeted therapy

HTML全文

参考文献(72)

[1]	中华医学会儿科学分会内分泌遗传代谢学组,中华医学会儿科学分会消化学组,中华医学会儿科学分会青春期医学专业委员会,等. 儿童非酒精性脂肪肝病诊断与治疗专家共识[J]. 中国实用儿科杂志,2018,33(7):487-492.
[2]	Schwimmer J B. Clinical advances in pediatric nonalcoholic fatty liver disease[J]. Hepatology,2016,63(5):1718-1725. doi: 10.1002/hep.28441
[3]	Moran J R,Ghishan F K,Halter S A,et al. Steatohepatitis in obese children: A cause of chronic liver dysfunction[J]. Am J Gastroenterol,1983,78(6):374-377.
[4]	Zhou F,Zhou J,Wang W,et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis[J]. Hepatology,2019,70(4):1119-1133. doi: 10.1002/hep.30702
[5]	Anderson E L,Howe L D,Jones H E,et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: A systematic review and meta-analysis[J]. PLoS One,2015,10(10):e0140908. doi: 10.1371/journal.pone.0140908
[6]	Zhu Y,Liu R,Shen Z,et al. Combination of luteolin and lycopene effectively protect against the "two-hit" in NAFLD through Sirt1/AMPK signal pathway[J]. Life Sci,2020,256:117990. doi: 10.1016/j.lfs.2020.117990
[7]	Fang Y L,Chen H,Wang C L,et al. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model"[J]. World J Gastroenterol,2018,24(27):2974-2983. doi: 10.3748/wjg.v24.i27.2974
[8]	Mills S,Stanton C,Lane J A,et al. Precision nutrition and the microbiome,part I: Current state of the science[J]. Nutrients,2019,11(4):923. doi: 10.3390/nu11040923
[9]	Tun H M,Bridgman S L,Chari R,et al. Roles of birth mode and infant gut microbiota in intergenerational transmission of overweight and obesity from mother to offspring[J]. JAMA Pediatr,2018,172(4):368-377. doi: 10.1001/jamapediatrics.2017.5535
[10]	Sarkar A,Yoo J Y,Valeria Ozorio Dutra S,et al. The association between early-life gut microbiota and long-term health and diseases[J]. J Clin Med,2021,10(3):459. doi: 10.3390/jcm10030459
[11]	Hollister E B,Riehle K,Luna R A,et al. Structure and function of the healthy pre-adolescent pediatric gut microbiome[J]. Microbiome,2015,3:36. doi: 10.1186/s40168-015-0101-x
[12]	Singh R,Zogg H,Wei L,et al. Gut microbial dysbiosis in the pathogenesis of gastrointestinal dysmotility and metabolic disorders[J]. J Neurogastroenterol Motil,2021,27(1):19-34. doi: 10.5056/jnm20149
[13]	Oliphant K,Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health[J]. Microbiome,2019,7(1):91. doi: 10.1186/s40168-019-0704-8
[14]	Zhao Z H,Lai J K,Qiao L,et al. Role of gut microbial metabolites in nonalcoholic fatty liver disease[J]. J Dig Dis,2019,20(4):181-188. doi: 10.1111/1751-2980.12709
[15]	陈恬,秦琴,刘善荣. 肠道菌群在肝病领域的研究现状及应用展望[J]. 中华检验医学杂志,2019,42(3):170-175.
[16]	Volta U,Bonazzi C,Bianchi F B,et al. IgA antibodies to dietary antigens in liver cirrhosis[J]. Ric Clin Lab,1987,17(3):235-242. doi: 10.1007/BF02912537
[17]	Tripathi A,Debelius J,Brenner D A,et al. Publisher correction: The gut-liver axis and the intersection with the microbiome[J]. Nat Rev Gastroenterol Hepatol,2018,15(12):785. doi: 10.1038/s41575-018-0031-8
[18]	De Munck TJI,Xu P,Verwijs HJA,et al. Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis[J]. Liver Int,2020,40(12):2906-2916. doi: 10.1111/liv.14696
[19]	张晶. 肠道微生物与儿童非酒精性脂肪性肝病关系的研究进展[J]. 国际儿科学杂志,2020,47(8):522-527.
[20]	Kuang L,Zhou W,Jiang Y. Association of small intestinal bacterial overgrowth with nonalcoholic fatty liver disease in children: A meta-analysis[J]. PLoS One,2021,16(12):e0260479. doi: 10.1371/journal.pone.0260479
[21]	Zhu L,Baker S S,Gill C,et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH[J]. Hepatology,2013,57(2):601-609. doi: 10.1002/hep.26093
[22]	Del Chierico F,Nobili V,Vernocchi P,et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach[J]. Hepatology,2017,65(2):451-464. doi: 10.1002/hep.28572
[23]	Schwimmer J B,Johnson J S,Angeles J E,et al. Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease[J]. Gastroenterology,2019,157(4):1109-1122. doi: 10.1053/j.gastro.2019.06.028
[24]	凌剑蓉,章殷捷,张智慧,等. 非酒精性脂肪性肝病儿童肠道菌群特异性的变化[J]. 中华儿科杂志,2018,56(11):850-855.
[25]	Ley R E,Turnbaugh P J,Klein S,et al. Microbial ecology: Human gut microbes associated with obesity[J]. Nature,2006,444(7122):1022-1023. doi: 10.1038/4441022a
[26]	den Besten G,Lange K,Havinga R,et al. Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids[J]. Am J Physiol Gastrointest Liver Physiol,2013,305(12):G900-G910. doi: 10.1152/ajpgi.00265.2013
[27]	Cani P D,Van Hul M,Lefort C,et al. Microbial regulation of organismal energy homeostasis[J]. Nat Metab,2019,1(1):34-46. doi: 10.1038/s42255-018-0017-4
[28]	贺文娟,钟燕. 肠道菌群及其代谢产物与肥胖的关系[J]. 国际内分泌代谢杂志,2018,38(1):40-43.
[29]	Michail S,Lin M,Frey M R,et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease[J]. FEMS Microbiol Ecol,2015,91(2):1-9.
[30]	Delzenne N M,Knudsen C,Beaumont M,et al. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis[J]. Proc Nutr Soc,2019,78(3):319-328. doi: 10.1017/S0029665118002756
[31]	de Medeiros IC,de Lima JG. Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease? - A mechanistic hypothesis[J]. Med Hypotheses,2015,85(2):148-152. doi: 10.1016/j.mehy.2015.04.021
[32]	Engstler A J,Aumiller T,Degen C,et al. Insulin resistance alters hepatic ethanol metabolism: Studies in mice and children with non-alcoholic fatty liver disease[J]. Gut,2016,65(9):1564-1571. doi: 10.1136/gutjnl-2014-308379
[33]	Chen J,Zheng M,Liu J,et al. Ratio of conjugated chenodeoxycholic to muricholic acids is associated with severity of nonalcoholic steatohepatitis[J]. Obesity (Silver Spring),2019,27(12):2055-2066. doi: 10.1002/oby.22627
[34]	Clifford B L,Sedgeman L R,Williams K J,et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption[J]. Cell Metab,2021,33(8):1671-1684. doi: 10.1016/j.cmet.2021.06.012
[35]	Chávez-Talavera O,Tailleux A,Lefebvre P,et al. Bile acid control of metabolism and inflammation in obesity,type 2 diabetes,dyslipidemia,and nonalcoholic fatty liver disease[J]. Gastroenterology,2017,152(7):1679-1694. doi: 10.1053/j.gastro.2017.01.055
[36]	Chiang J Y L,Ferrell J M. Bile acids as metabolic regulators and nutrient sensors[J]. Annu Rev Nutr,2019,39:175-200. doi: 10.1146/annurev-nutr-082018-124344
[37]	Jiao N,Baker S S,Chapa-Rodriguez A,et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD[J]. Gut,2018,67(10):1881-1891. doi: 10.1136/gutjnl-2017-314307
[38]	Shi Z,Chen G,Cao Z,et al. Gut microbiota and its metabolite deoxycholic acid contribute to sucralose consumption-induced nonalcoholic fatty liver disease[J]. J Agric Food Chem,2021,69(13):3982-3991. doi: 10.1021/acs.jafc.0c07467
[39]	Nimer N,Choucair I,Wang Z,et al. Bile acids profile,histopathological indices and genetic variants for non-alcoholic fatty liver disease progression[J]. Metabolism,2021,116:154457. doi: 10.1016/j.metabol.2020.154457
[40]	Ticho A L,Malhotra P,Dudeja P K,et al. Intestinal absorption of bile acids in health and disease[J]. Compr Physiol,2019,10(1):21-56.
[41]	Craciun S,Balskus E P. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme[J]. Proc Natl Acad Sci U S A,2012,109(52):21307-21312. doi: 10.1073/pnas.1215689109
[42]	Sherriff J L,O'Sullivan T A,Properzi C,et al. Choline,its potential role in nonalcoholic fatty liver disease,and the case for human and bacterial genes[J]. Adv Nutr,2016,7(1):5-13. doi: 10.3945/an.114.007955
[43]	Ji Y,Yin Y,Sun L,et al. The molecular and mechanistic insights based on gut-liver axis: Nutritional target for non-alcoholic fatty liver disease (NAFLD) improvement[J]. Int J Mol Sci,2020,21(9):3066. doi: 10.3390/ijms21093066
[44]	Tan X,Liu Y,Long J,et al. Trimethylamine n-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease[J]. Mol Nutr Food Res,2019,63(17):e1900257. doi: 10.1002/mnfr.201900257
[45]	Ye J Z,Li Y T,Wu W R,et al. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis[J]. World J Gastroenterol,2018,24(23):2468-2481. doi: 10.3748/wjg.v24.i23.2468
[46]	Gao X,Liu X,Xu J,et al. Dietary trimethylamine n-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet[J]. J Biosci Bioeng,2014,118(4):476-481. doi: 10.1016/j.jbiosc.2014.03.001
[47]	Dumas M E,Rothwell A R,Hoyles L,et al. Microbial-host co-metabolites are prodromal markers predicting phenotypic heterogeneity in behavior,obesity,and impaired glucose tolerance[J]. Cell Rep,2017,20(1):136-148. doi: 10.1016/j.celrep.2017.06.039
[48]	Dumas M E,Barton R H,Toye A,et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice[J]. Proc Natl Acad Sci U S A,2006,103(33):12511-12516. doi: 10.1073/pnas.0601056103
[49]	S Lavekar A,V Raje D,Manohar T,et al. Role of probiotics in the treatment of nonalcoholic fatty liver disease: A meta-analysis[J]. Euroasian J Hepatogastroenterol,2017,7(2):130-137.
[50]	Fei N,Bruneau A,Zhang X,et al. Endotoxin producers overgrowing in human gut microbiota as the causative agents for nonalcoholic fatty liver disease[J]. mBio,2020,11(1):e03263.
[51]	Kåhrström C T,Pariente N,Weiss U. Intestinal microbiota in health and disease[J]. Nature,2016,535(7610):47. doi: 10.1038/535047a
[52]	Chen Y,Jin Y,Stanton C,et al. Alleviation effects of bifidobacterium breve on dss-induced colitis depends on intestinal tract barrier maintenance and gut microbiota modulation[J]. Eur J Nutr,2021,60(1):369-387. doi: 10.1007/s00394-020-02252-x
[53]	Sun Q,Zhang S,Liu X,et al. Effects of a probiotic intervention on escherichia coli and high-fat diet-induced intestinal microbiota imbalance[J]. Appl Microbiol Biotechnol,2020,104(3):1243-1257. doi: 10.1007/s00253-019-10304-4
[54]	Alisi A,Bedogni G,Baviera G,et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther,2014,39(11):1276-1285. doi: 10.1111/apt.12758
[55]	Famouri F,Shariat Z,Hashemipour M,et al. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents[J]. J Pediatr Gastroenterol Nutr,2017,64(3):413-417. doi: 10.1097/MPG.0000000000001422
[56]	Singh S P,Jadaun J S,Narnoliya L K,et al. Prebiotic oligosaccharides: Special focus on fructooligosaccharides,its biosynthesis and bioactivity[J]. Appl Biochem Biotechnol,2017,183(2):613-635. doi: 10.1007/s12010-017-2605-2
[57]	Nicolucci A C,Hume M P,Martínez I,et al. Prebiotics reduce body fat and alter intestinal microbiota in children who are overweight or with obesity[J]. Gastroenterology,2017,153(3):711-722. doi: 10.1053/j.gastro.2017.05.055
[58]	Ho J,Nicolucci A C,Virtanen H,et al. Effect of prebiotic on microbiota,intestinal permeability,and glycemic control in children with type 1 diabetes[J]. J Clin Endocrinol Metab,2019,104(10):4427-4440. doi: 10.1210/jc.2019-00481
[59]	Abdel-Razik A,Mousa N,Shabana W,et al. Rifaximin in nonalcoholic fatty liver disease: Hit multiple targets with a single shot[J]. Eur J Gastroenterol Hepatol,2018,30(10):1237-1246. doi: 10.1097/MEG.0000000000001232
[60]	Jian J,Nie MT,Xiang B,et al. Rifaximin ameliorates non-alcoholic steatohepatitis in mice through regulating gut microbiome-related bile acids[J]. Front Pharmacol,2022,13:841132. doi: 10.3389/fphar.2022.841132
[61]	Hwang I,Park Y J,Kim Y R,et al. Alteration of gut microbiota by vancomycin and bacitracin improves insulin resistance via glucagon-like peptide 1 in diet-induced obesity[J]. FASEB J,2015,29(6):2397-2411. doi: 10.1096/fj.14-265983
[62]	中华医学会肠外肠内营养学分会,中国国际医疗保健促进交流会加速康复外科分会,中国微生态治疗创新联盟,等. 菌群移植标准化方法学的建立与临床应用中国专家共识[J]. 中华胃肠外科杂志,2020,23(Z1):5-13. doi: 10.3760/cma.j.cn.441530-20200420-00231
[63]	Zhou D,Pan Q,Shen F,et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota[J]. Sci Rep,2017,7(1):1529. doi: 10.1038/s41598-017-01751-y
[64]	Craven L,Rahman A,Nair Parvathy S,et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial[J]. Am J Gastroenterol,2020,115(7):1055-1065. doi: 10.14309/ajg.0000000000000661
[65]	Leong K S W,Jayasinghe T N,Wilson B C,et al. Effects of fecal microbiome transfer in adolescents with obesity: The gut bugs randomized controlled trial[J]. JAMA Netw Open,2020,3(12):e2030415. doi: 10.1001/jamanetworkopen.2020.30415
[66]	杨蕊旭,周达,范建高. 靶向肠道菌群代谢产物防治非酒精性脂肪性肝病[J]. 实用肝脏病杂志,2017,20(6):643-646.
[67]	周达,范建高. 肠道菌群-SCFAs在代谢性疾病中的作用研究[J]. 胃肠病学和肝病学杂志,2016,25(3):330-332.
[68]	Deng M,Qu F,Chen L,et al. SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD[J]. J Endocrinol,2020,245(3):425-437. doi: 10.1530/JOE-20-0018
[69]	Ye J,Lv L,Wu W,et al. Butyrate protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis by improving gut barrier function,attenuating inflammation and reducing endotoxin levels[J]. Front Microbiol,2018,9:1967. doi: 10.3389/fmicb.2018.01967
[70]	Thomas C,Gioiello A,Noriega L,et al. TGR5-mediated bile acid sensing controls glucose homeostasis[J]. Cell Metab,2009,10(3):167-177. doi: 10.1016/j.cmet.2009.08.001
[71]	Jia W,Xie G,Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis[J]. Nat Rev Gastroenterol Hepatol,2018,15(2):111-128. doi: 10.1038/nrgastro.2017.119
[72]	Jiang C,Xie C,Lv Y,et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction[J]. Nat Commun,2015,6:10166. doi: 10.1038/ncomms10166

计量

文章访问数: 2940
HTML全文浏览量: 2258
PDF下载量: 29
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

肠道菌群与儿童非酒精性脂肪性肝病的研究进展

doi: 10.12259/j.issn.2095-610X.S20230708

作者简介:
李露（1995～），女，四川资阳人，在读硕士研究生，主要从事儿科消化临床工作

通讯作者:
田云粉，E-mail：136506595@qq.com

计量

Research Progress on Intestinal Microflora and Non-alcoholic Fatty Liver Disease in Children

计量

目录

[1]	代怡琳, 田云粉. 药物在儿童结肠镜检查前肠道准备的应用及研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20241024
[2]	李波, 孙杨, 缪应雷. 炎症性肠病的肠道微生态变化及对策, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240401
[3]	胡伟, 李金男, 杨伟, 苏黎, 喻卓, 陈志松. 儿童肌部室间隔缺损的介入治疗研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240307
[4]	聂忠顺, 缪应雷. 生物制剂背景下粪菌移植对炎症性肠病的应用前景, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20241023
[5]	陈杭, 崔琦, 黄敏杉, 刘建军, 马岚青. miRNA在非酒精性脂肪性肝病中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240101
[6]	牛俊杰, 姬文娟, 于拽拽. 肠道菌群、血清ET、PCT水平与脓毒症病情程度、预后的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240420
[7]	李媛媛, 宋亚贤, 徐玉善, 曾晓甫, 袁惠, 徐兆, 江艳. 肠道菌群代谢物TMAO与非酒精性脂肪性肝病的关系, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240210
[8]	李抒瑾, 杨艳飞, 苏敏, 凌昱, 饶艳琼, 崔继华. 儿童注意缺陷多动障碍共病情绪问题的单核苷酸多态性研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230420
[9]	李丹, 万绪莲, 李律宇, 云宇, 罗光云, 刘韦兵, 林公府, 李宁, 黎勇坤, 段为钢. 尿酸酶缺失大鼠肠道菌群的变化, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230205
[10]	张学敏, 田云粉. 胆汁酸代谢异常在非酒精性脂肪性肝病发展中的作用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231125
[11]	陆小华, 袁洪新. BTLA、CTLA-4基因多态性与肝癌TACE联合靶向治疗疗效及预后相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230927
[12]	张莹, 高虹, 张翠香, 陈泽莹, 邹红群, 李丽琼, 杨巨品, 胡月新. 儿童幽门螺杆菌感染情况及其与缺铁性贫血的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220418
[13]	杨顺航, 李炯明, 刘建和, 王光, 李沛. 肠源性高草酸尿症的发病机制与治疗进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220734
[14]	杨永锐, 王丽媛, 李海雯, 赵智蓉, 普瑞, 吴贵帅, 李树德. 灯盏乙素抑制NOX的表达改善非酒精性脂肪性肝病肝脏纤维化的研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220721
[15]	刘四香, 黄永坤, 王明英, 胡红卫, 马敏, 凌昱. 功能性便秘患儿的肠道菌群分析及治疗干预, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220309
[16]	黄海林, 李小娟, 尹建雯, 蒋鸿超. 2017年至2020年儿童感染性腹泻沙门菌和志贺菌分布及药敏结果, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210713
[17]	徐永芳, 吴娜, 胡月新, 赵永美, 郑绍鼎, 危玲, 郑思佳, 刘建军. GW7647对大鼠非酒精性脂肪性肝病（NAFLD）的治疗作用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210804
[18]	薛平燕, 江艳, 徐玉善, 袁惠, 李璇, 宋亚贤, 刘华. 肠道菌群结构在非酒精性脂肪性肝病患者中的改变, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20201120
[19]	盛晓翠. 儿童泌尿系感染的病原菌分析, 昆明医科大学学报.
[20]	. 闭合复位克氏针固定治疗儿童肱骨髁上不稳定骨折, 昆明医科大学学报.

留言板

肠道菌群与儿童非酒精性脂肪性肝病的研究进展

doi: 10.12259/j.issn.2095-610X.S20230708

作者简介: 李露（1995～），女，四川资阳人，在读硕士研究生，主要从事儿科消化临床工作

通讯作者: 田云粉，E-mail：136506595@qq.com

计量

出版历程

Research Progress on Intestinal Microflora and Non-alcoholic Fatty Liver Disease in Children

计量

出版历程

目录

作者简介:
李露（1995～），女，四川资阳人，在读硕士研究生，主要从事儿科消化临床工作

通讯作者:
田云粉，E-mail：136506595@qq.com